Affibody AB

Lonza

Uppgifter: Sanofi tar in bud på konsumenthälsodivision

Den franska läkemedelsjätten Sanofi ska enligt uppgifter ha bett om initiala bud för sin konsumenthälsoverksamhet, som är värderad till runt 20 miljarder dollar.

Olika bud om distansarbete – ”Vi ber vår personal att komma tillbaka till kontoret”

Hur viktigt är det för life science-bolagen att erbjuda distansarbete? Den frågan väckte debatt och fick många olika svar vid en paneldiskussion om talangrekryt...

Bakslag i studie för Astra Zenecas ADC-läkemedel

Astra Zenecas läkemedelskandidat Dato-DXd visade ingen signifikant förbättring av överlevnaden hos lungcancerpatienter i en fas III-studie.

“We aim to be a start-up company with an academic spirit”

Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working...

Gilead klarade inte målen i cancerstudie – aktien backade

Amerikanska Gilead rapporterar en betydande motgång i en cancerstudie med bolagets antikroppskonjugat Trodelvy.

Pfizer’s Paxlovid is being tested against post-COVID in a major Swedish study

In a new study conducted at the Karolinska University Hospital, Pfizer’s COVID drug, Paxlovid, is now being tested in patients with post-COVID. The study is one...

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Wusson Accelerator AB

How critical are the “Spermageddon” reports? – Researchers call for action

A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden s...

Hello Jenni Nordborg!

Life Science Sweden would like to know more about Jenni Nordborg and asks her about her new job, why she became a chemical engineer and who her role model is.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

Vinnova is going to establish a new innovation cluster

Vinnova, the Swedish Agency for Innovation Systems, has been commissioned by the government to establish a national innovation cluster for advanced medicines.

ZEISS Quality Innovation Summit video

An event full of experiences, talks, innovations, speeches, and state-of-the-art technology.

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

Optimize Courier SUPPLIERS (DISTRIBUTORS)

Saving lives worldwide with low-cost molecular diagnostics

High throughput testing for many upper respiratory tract pathogens thanks to automation technology

Rapid developments in AI – “All stakeholders are struggling to understand it”

Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, keeping up with developments is not easy....

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

Recipharm ingår samarbete med global koncern

Recipharm ingår ett strategiskt samarbete med den globala franska koncernen Product Life Group (PLG).

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...